GLP-1 Receptor Agonist [EPC]

448291 reported adverse events

Drugs of this class: LIRAGLUTIDE TIRZEPATIDE DULAGLUTIDE SEMAGLUTIDE EXENATIDE INSULIN DEGLUDEC AND LIRAGLUTIDE INSULIN GLARGINE AND LIXISENATIDE ORAL SEMAGLUTIDE

These side effects are most commonly reported by patients taking drugs of the GLP-1 Receptor Agonist [EPC] class:

# Side effect Count
0 NAUSEA 58700
1 INCORRECT DOSE ADMINISTERED 40780
2 BLOOD GLUCOSE INCREASED 36186
3 DIARRHOEA 29087
4 VOMITING 28701
5 INJECTION SITE PAIN 28511
6 WEIGHT DECREASED 24849
7 OFF LABEL USE 22366
8 DECREASED APPETITE 19062
9 DRUG INEFFECTIVE 17587
See all common reactions for GLP-1 Receptor Agonist [EPC]

Drugs of the GLP-1 Receptor Agonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ACCIDENTAL UNDERDOSE 7074 0.4910
1 IMPAIRED GASTRIC EMPTYING 6390 0.4683
2 EARLY SATIETY 837 0.4297
3 GASTROINTESTINAL HYPOMOTILITY 851 0.3772
4 THERAPEUTIC RESPONSE CHANGED 2271 0.3581
5 ERUCTATION 6904 0.3565
6 INJECTION SITE INJURY 1956 0.3524
7 EXTRA DOSE ADMINISTERED 13865 0.3419
8 FOOD CRAVING 1569 0.2978
9 HUNGER 3897 0.2795
See all enriched reactions for GLP-1 Receptor Agonist [EPC]